← Back

Enwei Pharmaceutical Co. Ltd. A

Enwei Pharmaceutical Co., Ltd. is a China-based company that researches, develops, produces, and sells Chinese medicines and chemical drugs. Its products cover areas such as gynecology, pediatrics, respiratory, stomatology, digestive, cardiovascular, hepatobiliary, and dermatology, marketed under brands including Jieeryin, Haowayou, and Likeshu. The company also offers a range of dosage forms and related products, including ointments, capsules, tablets, syrups, and medical devices. Founded in 1986, it is headquartered in Chengdu, China.

Country
Price · split & dividend adjusted
News & notes moving 301331.CS
301331.CS▼4

Enwei Pharmaceutical's 2026 Interim Report Shows Net Profit Down 58.21% Year-on-Year

Enwei Pharmaceutical released its 2026 interim report. Total operating revenue was 375 million yuan, down 16.62% year-on-year. Net profit attributable to the parent company was 16.0229 million yuan, down 58.21% from the same period last year. Net cash inflow from operating activities was 66.0645 million yuan, down 12.13% year-on-year. The company's asset-liability ratio was 28.92%, gross margin was 51.18%, and diluted earnings per share was 0.16 yuan, down 59.51% year-on-year. The number of shareholders was 6,714, and the top ten shareholders held 69.42% of the shares.
301331.CS ▼
Jiemian·23dRead more →
301331.CS▲2

Enwei Pharmaceutical's Controlling Shareholder Unfreezes 138,000 Shares, Cumulative Frozen Shares Reduced to Zero

Enwei Pharmaceutical's controlling shareholder, Chengdu Enwei Investment Group, has had 138,000 shares unfrozen, representing 0.53% of its holdings and 0.13% of the company's total share capital. As a result, the cumulative number of frozen shares held by the controlling shareholder and its concert parties has been reduced to zero. In the first quarter of 2026, the company achieved revenue of 175 million yuan and net profit attributable to the parent company of 12.5 million yuan.
301331.CS ▲
财中社·64dRead more →
© 2026 MarketDXAsset